Skip to main content

Table 2 Amino acid concentration in aqueous, vitreous and serum

From: Case report: Aqueous and Vitreous amino-acid concentrations in a patient with maple syrup urine disease operated on rhegmatogenous retinal detachment

Amino acid

Aqueous (μM)

Vitreous (μM)

Serum (μM)

MSUD

Wuu et al.a

Durhamb

Wakabayashi et al.c

MSUD

Bertram et al.d

Diederen et al.e

Durhamb

Honkanen et al.f

Asensio et al.g

Yalcinbayir et al.h

MSUD

LAB

Aqueous control

Aqueous control

Aqueous control

Vitreous RRD

Vitreous control

Vitreous RRD

Vitreous control

Vitreous control

Vitreous control

Vitreous RD,MH,ERM

Vitreous Control

Normal

Pro

45

16.9 ± 15.4

16 ± 5.3

 

U

    

4 ± 5.6

   

101

97–297

Tau

46

29.3 ± 12

39.1 ± 11.3

22.25 ± 8.36

21

  

26.0 ± 7.8

22.6 ± 6.6

28.8 ± 5

 

11.9 ± 1.3

79(26–146)

61

27–95

Asp

3

13.4 ± 9.1

1 ± 1.5

1.81 ± 1.04

3

U

1.1 ± 0.8

6.7 ± 2.8

6.6 ± 2.5

1.7 ± 1.5

1.4 ± 1.0

3.7 ± 4.1

47(6–70)

5

2–9

Thr

158

106.7 ± 18.9

152 ± 41.4

 

31

    

73.6 ± 10.3

85.5 ± 28.4

61.8 ± 3.6

385(77–519)

130

92–180

Ser

131

111.2 ± 45.3

179 ± 38.1

 

89

    

106 ± 24.4

103.9 ± 24.4

79.2 ± 19.5

501(96–733)

99

89–165

Asn

78

27.3 ± 11.1

49.2 ± 11.5

 

39

    

24.3 ± 4.3

35.8 ± 11.6

19.5 ± 8.1

 

80

32–92

Glu

6

39.5 ± 18.8

12 ± 3.4

2.98 ± 1.12

U

13.4 ± 11.9

1.7 ± 0.8

16.6 ± 5.6

13.1 ± 5.2

14.5 ± 11

5.2 ± 2.3

3.8 ± 5.1

20(10–82)

96

6–62

Gln

658

95.9 ± 68.9

717 ± 134

 

627

     

1192.9 ± 404.4

 

3386(714–4698)

599

466–798

Gly

71

7 ± 3.2

16.7 ± 3.5

 

5

U

4 ± 2.7

42.5 ± 32.0

49.4 ± 36.3

8.7 ± 2.6

8.5 ± 2.5

10.2 ± 6.2

56(15–196)

256

147–299

Ala

227

182.7 ± 91.4

294 ± 66.1

105.98 ± 9.88

85

U

88.4 ± 35

  

126 ± 15.6

159.5 ± 54.9

31.8 ± 10.6

896(125–1842)

241

146–494

Cit

6

3.8 ± 6.6

9.8 ± 4.8

 

6

    

8.3 ± 1.6

  

9(5–27)

18

19–47

Abu

10

10.6 ± 5.7

31.4 ± 7.8

 

U

    

14.4 ± 1.7

   

9

15–35

Val

146

281.2 ± 180.6

388 ± 84.5

 

67

U

112 ± 4.4

  

174 ± 41.3

 

87.5 ± 6.5

909(140–1277)

95

179–335

Cys

9

7.9 ± 1.7

11.2 ± 3.5

 

4

    

6.5 ± 6

   

42

24–54

Met

23

18.8 ± 8.6

44.4 ± 9.9

 

13

    

24.7 ± 5

22.3 ± 8.1

13.2 ± 3.2

84(12–133)

13

13–37

Ile

52

72.2 ± 26.2

79.8 ± 6.9

 

32

U

28.3 ± 12.0

  

37.6 ± 3.4

37.9 ± 11.6

32.8 ± 5.1

220(39–317)

27

46–90

Leu

132

169.5 ± 72.2

192 ± 39.6

 

72

U

63.5 ± 21.9

  

96.1 ± 20.5

89.7 ± 28.4

76.5 ± 5.3

584(93–737)

88

113–205

Tyr

58

79.2 ± 37.6

123 ± 16.5

 

32

U

31.9 ± 3.7

  

51.8 ± 12.3

58.2 ± 18.8

41.1 ± 6.3

365(58–399)

29

37–77

Phe

55

97.7 ± 30.3

119 ± 14

 

28

U

31.7 ± 11

  

56.8 ± 13.6

44.4 ± 14.2

43.3 ± 1.9

356(66–469)

29

46–74

Orn

22

15 ± 3.4

25.3 ± 4.6

 

15

    

16 ± 1.1

 

13.6 ± 0.9

 

42

55–135

Lys

168

110.3 ± 36.5

155 ± 23.5

 

114

    

105 ± 14.4

115.4 ± 33.7

87.6 ± 4.6

 

137

135–243

His

60

47.6 ± 9.5

77.9 ± 12.7

 

29

    

40.7 ± 13.8

38.4 ± 10.0

  

62

72–108

Trp

36

U

31.9 ± 10

 

U

    

18.3 ± 7

 

7.4 ± 1.2

 

24

n/a

Arg

100

29.2 ± 13

133 ± 26

 

66

U

52.7 ± 46.0

  

71.9 ± 10.2

 

62.3 ± 10.5

 

46

28–96

  1. MSUD maple syrup urine disease-i.e., our patient, μM μmol/l, U unmeasurable; empty cells refer to not available data
  2. MH macular hole, ERM epiretinal membrane, a.c. anterior chamber, RRD rhegmatogenous retinal detachment, TRD tractional retinal detachment, PPV pars plana vitrectomy, LAB(normal) normal reference values provided by the laboratory that performed the amino acid analysis
  3. Data regarding previous studies
  4. a Wuu et al. [4]: Controls: Aqueous: n = 3 (ophthalmological emergency operations - Chinese population)
  5. bDurham [5]: Controls: Aqueous: normal eyes, a.c. paracentesis (n = 9, mean age 28y (2.5–77). Vitreous: procedure with vitreous loss (n = 3, Marfan/cataract/enucleation, age = 40/21/35 y)
  6. c Wakabayashi et al. [6]: Controls: cataract without other ocular disease (n = 9, age 66.1 ± 12.8 y.)
  7. d Bertram et al. [7]: PPV for RRD (n = 5, age =63.8 ± 15.5 y., duration 52.4 ± 65.4 days). Controls: vitrectomy for MH (n = 7) or ERM (n = 3) (age =66.1 ± 12.1 y.)
  8. e Diederen et al. [3]: PPV for primary retinal detachment (n = 114, age = 58.2 ± 15.1 y., duration 43.6 ± 72.1 days). Controls: PPV for MH or ERM (n = 52, age = 51.3 ± 14.0 y.)
  9. f Honkanen et al. [8]: Controls: PPV for MH (n = 10 [2 RRD]), ERM(n = 6[2 TRD]), MH and ERM (n = 1). Total number of eyes: (n = 17, age = 68 ± 14 y.)
  10. g Asensio et al. [9]: 64 eyes with RRD n = (45), MH (n = 5) and ERM (n = 14). Age = 67.7 ± 14.2 y. [No statistically significant difference neither between groups, nor regarding age]
  11. h Yalcinbayir et al. [10]: Controls: PPV for MH(n = 6), subluxated lens (n = 1). Age = 67.3 ± 3.8 y
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us